Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature. 2022

Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
Department of Medical Oncology, Institut Paoli-Calmettes, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Institut Paoli-Calmettes Neuroendocrine Tumor (IPC NET) Center, Marseille, France.

Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007340 Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA. Adenoma, beta-Cell,Insuloma,beta-Cell Tumor,Adenoma, beta Cell,Adenomas, beta-Cell,Insulinomas,Insulomas,Tumor, beta-Cell,Tumors, beta-Cell,beta Cell Tumor,beta-Cell Adenoma,beta-Cell Adenomas,beta-Cell Tumors
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
February 2018, Clinical endocrinology,
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
May 2013, JOP : Journal of the pancreas,
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
April 2016, Hormones (Athens, Greece),
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
January 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.],
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
March 2022, Clinical case reports,
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
August 2023, The New England journal of medicine,
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
April 2023, Cureus,
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
July 2016, Neuro endocrinology letters,
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
December 2007, Journal of experimental & clinical cancer research : CR,
Sandrine Oziel-Taieb, and Jemima Maniry-Quellier, and Brice Chanez, and Flora Poizat, and Jacques Ewald, and Patricia Niccoli
July 1978, The New England journal of medicine,
Copied contents to your clipboard!